Ismaheel O Lawal, Olumide B Gbolahan, Charles Marcus, Aaron T Jones, Walid L Shaib, Saima Muzahir
{"title":"Feasibility and Safety of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Neuroendocrine Tumor in a Patient With Sickle Cell Anemia.","authors":"Ismaheel O Lawal, Olumide B Gbolahan, Charles Marcus, Aaron T Jones, Walid L Shaib, Saima Muzahir","doi":"10.1097/RLU.0000000000005790","DOIUrl":null,"url":null,"abstract":"<p><p>A 56-year-old woman with sickle cell anemia (SCA) and metastatic neuroendocrine tumor refractory to somatostatin analog received 4 cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The treatment schedule was delayed by multiple episodes of hospitalizations related to underlying SCA. PRRT was well-tolerated with stable renal, hematologic, and liver lab parameters. After PRRT, the disease remained stable for up to 13 months, and serum chromogranin levels declined by 45%. PRRT with 177Lu-DOTATATE can be safely administered for metastatic neuroendocrine tumors in patients with SCA with good anti-tumor effect. Disruption to the therapy schedule should be anticipated, given the potential for recurrent hospitalization for illnesses related to the underlying SCA.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005790","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
A 56-year-old woman with sickle cell anemia (SCA) and metastatic neuroendocrine tumor refractory to somatostatin analog received 4 cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The treatment schedule was delayed by multiple episodes of hospitalizations related to underlying SCA. PRRT was well-tolerated with stable renal, hematologic, and liver lab parameters. After PRRT, the disease remained stable for up to 13 months, and serum chromogranin levels declined by 45%. PRRT with 177Lu-DOTATATE can be safely administered for metastatic neuroendocrine tumors in patients with SCA with good anti-tumor effect. Disruption to the therapy schedule should be anticipated, given the potential for recurrent hospitalization for illnesses related to the underlying SCA.
期刊介绍：
Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty.
Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
